Announcing the acquisition of Bactana®, Kemin Nutrisurance: Pet Food and Rendering Technologies has expanded its gut health portfolio. As part of this integration, Kemin aims to leverage its resources and scientific expertise to accelerate the development of innovative solutions for intestinal health.
Kemin Industries, a global ingredient manufacturer, has announced the acquisition of Bactana®, a research-driven company specializing in advancements in intestinal health and fermentation technology for animals. Bactana was launched from Cornell University’s McGovern Center in 2017 and currently operates from UConn’s Technology Incubation Program (TIP).
The company points to this strategic investment by Kemin Nutrisurance: Pet Food and Rendering Technologies as underscoring its commitment to scientific innovation and the continuous expansion of its expertise in gut health.
“Compelled by curiosity, we are reinforcing our dedication to developing novel solutions that support metabolism, immune function, and overall well-being by combining Bactana’s cutting-edge research with our existing expertise,” said Kimberly Nelson, President of Kemin Nutrisurance. “This acquisition aligns with our long-term vision to explore emerging technologies in intestinal health and further strengthen our position as an industry leader.”
As part of this integration, Kemin Nutrisurance will leverage its global resources and scientific expertise to advance research and accelerate the development of innovative solutions in this evolving field. The company regards the acquisition as representing another step forward in its mission to enhance health and nutrition through pioneering science and technology.
“We are incredibly grateful to our employees, advisors, and shareholders for their support and confidence in our vision over the past six years, and we believe Kemin is the ideal partner to help advance our technology and expand its potential global impact,” expressed John Kallassy, CEO of Bactana Corp.
